- Home
- RFI vs SRZN Comparison
RFI vs SRZN Comparison
Compare RFI & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RFI | SRZN |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | United States | United States |
| Employees | N/A | 59 |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.3M | 271.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | RFI | SRZN |
|---|---|---|
| Price | $10.59 | $29.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $38.00 |
| AVG Volume (30 Days) | 78.8K | ★ 551.0K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 8.25% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,477,000.00 |
| Revenue This Year | N/A | $75.35 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.57 | $11.39 |
| 52 Week High | $12.17 | $35.86 |
Technical Indicators
Market Signals| Indicator | RFI | SRZN |
|---|---|---|
| Relative Strength Index (RSI) | 25.34 | 66.66 |
| Support Level | N/A | $24.64 |
| Resistance Level | $11.24 | $33.96 |
| Average True Range (ATR) | 0.13 | 2.32 |
| MACD | -0.04 | 1.24 |
| Stochastic Oscillator | 4.86 | 62.33 |
Price Performance
Historical ComparisonAbout RFI Cohen & Steers Total Return Realty Fund Inc.
Cohen & Steers Total Return Realty Fund Inc is a diversified closed-end management investment company. Its investment objective is to achieve a high total return through investment in real estate securities. The Fund invests majority of its total assets in the equity securities of real estate companies under normal circumstances, which includes common shares, REITs, rights or warrants, convertible securities, and preferred shares.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).